Vanderbilt University has received a five-year grant from the National Institutes of Health (NIH) to establish the Tennessee Center for AIDS Research with Meharry Medical College and the Tennessee Department of Health.

Inhibitors of the enzyme phospholipase D1 suppress the replication of HIV-1, Vanderbilt investigators have discovered.

With the help of a computer program called “Rosetta,” researchers at Vanderbilt University have “redesigned” an antibody that has increased potency and can neutralize more strains of the AIDS-causing human immunodeficiency virus (HIV) than can any known natural antibody.

New findings underscore the attractiveness of the HIV capsid – the structure that encloses the viral genome – as a therapeutic target.

If you’re a native of rural Mozambique who contracts HIV and becomes symptomatic, before seeking clinical testing and treatment, you’ll likely consult a traditional healer.

Vanderbilt University’s Richard Caprioli, Ph.D., is participating in a national, federally funded collaboration to develop an intravaginal ring capable of delivering antiretroviral drugs to women at risk for HIV infection.

Understanding how HIV infection affects immune system B cells may guide strategies for vaccine development.